South Korea Companion Diagnostics Oncology Market

South Korea Companion Diagnostics Oncology Market Size

As per the survey report on South Korea companion diagnostics oncology market, the market is expected to foresee a CAGR value of 14.5% during 2026-2036, and further generate a market size of USD 1215.2 million by the end of 2036. In 2025, the market size was value at USD 271.1 million revenue.

• The South Korea companion diagnostics oncology market’s growth is driven by increased investment in biomedical research.
• KDMI analyst’s growth analysis foresees regulation complexities as restraint for South Korea companion diagnostics oncology market.
• In the South Korea companion diagnostics oncology market, technology segment is playing significant role.

South Korea Companion Diagnostics Oncology Market Analysis

In oncology, a companion diagnostic (CDx) is a specialized test that identifies if a patient is in a good condition for a specific targeted cancer therapy. By analyzing a patient's tumor for specific genetic mutations or biomarkers, it helps doctors select the most effective drugs while minimizing severe side effects. The South Korea companion diagnostics oncology market is the increasing prevalence of cancer. According to reports, cancer is the leading cause of death in Korea. In 2021, there were approximately 280,000 new cancer cases that were diagnosed, and over 26% of total deaths were associated to cancer. The rising burden of cancer cases across Korea is further accelerating advancement in therapies. Furthermore, the growing emphasis on precision medicine is poised as significant growth factor for South Korea companion diagnostics oncology market.

South Korea Companion Diagnostics Oncology Market Growth Drivers and Restraints

Growth Drivers

• Increased investment in cancer research – Increasing investment in cancer research is a key factor driving the growth of the South Korea companion diagnostics oncology market. The South Korean government, research institutions, and pharmaceutical companies are actively investing in oncology-focused research programs to improve treatment and therapy solutions. Recently, a collaboration between U.S and Korea had invested in Korean oncology R&D ecosystem. The Korea U.S Collaborative Research Fund of USD 4.4 million was allocated into a project led by Korea Advanced Institute of Science and Technology (KAIST), with the aim to develop human-relevant cancer drug screening platforms. This collaborative investment poses as a key factor for market expansion in South Korea. Additionally, rising collaborations between biotechnology companies, academic institutions, and healthcare providers are supporting advancements in genomics sequencing, thereby contributing to the market expansion.
• Growing demand for personalized medicine – The increasing demand for personalized medicine is contributing to the expansion of the South Korea companion diagnostics oncology market. Healthcare providers and patients are increasingly shifting toward individualized treatment approaches, based on patient’s genetic profile, tumor characteristics, and biomarker status. Korean medicines (KM) are well-known for their preventive care, holistic approach, and the use of premium ingredients. In 2021, approximately USD 110 million was invested across various ministries for Korean medicine R&D. A total of USD 131 million are announced to be allocated between 2020-2029 for the Korean Medicine Innovation Technology (KoMIT) development project. This rising investment in medicine R&D, is making personalized cancer treatment more accessible, thereby driving market demand.

Restraints

• Complex regulatory approval – The significant restraint is complex procedures to get approval from regulatory body for products and therapeutic solutions. The approval process can be time-consuming and costly, particularly for diagnostics tests linked to targeted cancer therapies. This can lead to delay in approvals and launch of advanced solutions, thereby reducing market growth potential.
• Limited accessibility in smaller healthcare facilities – Limited accessibility in smaller healthcare facilities and rural areas is posing as a significant challenge for South Korea companion diagnostics oncology market. Advanced companion diagnostics often require sophisticated laboratory infrastructure, which may not be available in rural regions, thereby limiting market growth.

South Korea Companion Diagnostics Oncology Market Segmentation

Our experts at KD Market Insights have segmented the South Korea companion diagnostics oncology market research report as:

Analyst’s Observation on South Korea Companion Diagnostics Oncology Market Recent Developments

Over the years, the experts at KD Market Insights have been observing the recent developments associated with South Korea companion diagnostics oncology market trends. Our expert’s market forecast analysis has recorded the market players adopting plentiful of key strategies including new product launches, mergers & acquisitions, and collaborations.

Lunit and CellCarta has entered into a significant partnership in March 2026. The partnership agreement indicates aim to accelerate adoption of AI-enabled digital pathology workflows across translational research, clinical trials and companion diagnostic (CDx) programs.

In September 2025, Illumina Inc announced to partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profiling test. The continued expansion of tumor-agnostic CDx claims underscores Illumina's commitment to advance access for patients to precision oncology care by generating standardized.

South Korea Companion Diagnostics Oncology Market Competitive Landscape

Some of the significant participants who top the South Korea companion diagnostics oncology market growth:

• T&L Co., Ltd
• DUK-IN
• SeohanCare Co., Ltd
• Solco Biomedical Co., Ltd
• Taeyeon Medical
• TDM Co., Ltd
• U&I Corporation
• INFINITT Healthcare
• Cybermed Inc
• OSTEOSYS Co., Ltd
• CG Bio Inc
• Woosam Medical